Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
NEW YORK (MarketWatch) -- Immucor Inc. (BLUD) said Tuesday the U.S. Food and Drug Administration has cleared Galileo Echo for marketing in the U.S. as of June 14. Echo, Immucor's third generation automated assay instrument, is a compact bench top, fully automated walk-away instrument for the small to medium sized hospital blood bank transfusion laboratory. The company believes the worldwide total available market for Echo is approximately 6,000.

Substantial growth prospects for this stock. Once a hospital adopts Immucor's testing machine, they are committed to buy Immucor's reagents. Current PE ratio is fully justified.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement